January 20th 2022
Greg Kunst, chief executive officer, Aurion Biotech, discussed the potential of cell therapy in treating people with corneal endothelial disease around the world.
December 13th 2021
Following GS030 optogenetic therapy, the first treated patient was able to locate and count objects on a table and could identify crosswalks in the street.
December 6th 2021
Findings from the phase 2 INFINITY trial identified dose-dependent safety outcomes of ADVM-022 in patients with diabetic macular edema.
November 21st 2021
The professor from University of Pittsburgh School of Medicine discussed the combination of an optogenetics device and gene therapy in treatment of RP.
November 19th 2021
The chief executive officer of California Retina Consultants discussed the positive results of RGX-314 gene therapy in wet AMD.
November 16th 2021
The Doheny Image Reading and Research Lab is leading a sub study to analyze OCT images with their proprietary 3D-OCTOR software.
April 6th 2021
Physician offers patient counseling pearls for selected retinal diseases.
November 13th 2020
The study presented at AAO provides an update on previously shared 6-month data from earlier this year.